Skip to content

Weight loss effect of synbiotics based on Lactobacillus plantarum lly-606 in obese patients: a single center, randomized, double-blind, placebo-controlled study

Weight loss effect of synbiotics based on Lactobacillus plantarum lly-606 in obese patients: a single center, randomized, double-blind, placebo-controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060837
Enrollment
Unknown
Registered
2022-06-12
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity

Interventions

test group:Oral synbiotics
Control group:Oral placebo

Sponsors

Department of gastrointestinal surgery, the First Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65; 2. 28<=BMI<=35Kg/m2 3. Be willing and able to follow the plan during the study and cooperate to complete various inspections during the test. Provide written informed consent before entering the study screening, and the patient has learned that he can withdraw from the study at any time without any loss;

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women who are in the reproductive period and do not take contraceptive measures; 2. Oral antibiotics nearly 1 month before enrollment; 3. Probiotics and prebiotic products were used 3 weeks before intervention; 4. People who have a fitness and fat reduction plan during the intervention period or plan to have gastric surgery; 5. Patients with severe gastrointestinal diseases; 6. Known allergy to synbiotics or similar products; 7. Patients without self-knowledge ability and persons with mental disorders; 8. Have a history of organ transplantation or malignant tumor diseases; 9. Use other test drugs at the same time or in other clinical trials; 10. Have a history of alcohol, tobacco and other drug abuse; 11. Those who are expected to be unable to complete the magnetic resonance examination; 12. Patients taking various kinds of mental disease control drugs; 13. Complicated with serious medical diseases or conditions: such as clinically serious (i.e. active) heart disease, serious and uncontrolled medical diseases and infections, serious uncontrollable digestive system disorders, serious electrolyte disorders, active disseminated intravascular coagulation, major organ failure, such as decompensated heart, lung, liver, kidney failure, peripheral neuropathy, etc.

Design outcomes

Primary

MeasureTime frame
body mass index;

Secondary

MeasureTime frame
Fecal flora;

Countries

China

Contacts

Public ContactJigang
Inte1385@163.com029-84771533

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026